Revance Therapeutics, Inc. (RVNC)
Feb 6, 2025 = RVNC was delisted (reason: acquired by Crown Laboratories)
3.650
0.00 (0.00%)
Inactive · Last trade price on Feb 6, 2025

Revance Therapeutics Revenue

Revance Therapeutics had revenue of $59.88M in the quarter ending September 30, 2024, with 10.66% growth. This brings the company's revenue in the last twelve months to $256.95M, up 25.82% year-over-year. In the year 2023, Revance Therapeutics had annual revenue of $234.04M with 76.55% growth.

Revenue (ttm)
$256.95M
Revenue Growth
+25.82%
P/S Ratio
n/a
Revenue / Employee
$430,394
Employees
597
Market Cap
383.05M

Revenue Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 2023234.04M101.48M76.55%
Dec 31, 2022132.57M54.77M70.40%
Dec 31, 202177.80M62.47M407.65%
Dec 31, 202015.33M14.91M3,610.65%
Dec 31, 2019413.00K-3.32M-88.92%
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro
Dec 31, 2014 Pro Pro Pro